Abata Therapeutics

Executive Director, Medical Affairs – APAC Regional Head

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Candidates should possess a strong background in medical affairs, ideally with a doctoral degree in a relevant scientific discipline such as pharmacy, medicine, or biology, and a minimum of 10 years of experience in the pharmaceutical or biotechnology industry. Experience in clinical development and medical affairs, specifically with Phase II/III programs, is highly desirable. Proven leadership skills and experience leading medical affairs teams are also required, along with a deep understanding of the APAC region's healthcare landscape and regulatory environment.

Responsibilities

The Regional Head of Medical and Clinical Affairs will lead and oversee the company’s medical affairs strategy and activities across the APAC region, developing and executing the APAC medical affairs strategy in alignment with global objectives, providing medical insights to support business and regulatory decisions, collaborating with cross-functional teams, ensuring the dissemination of accurate medical information, leading scientific communication efforts, developing and maintaining relationships with KOLs and HCPs, and providing medical expertise to support clinical trials and commercialization.

Skills

Medical Affairs

Clinical Development

Scientific Communication

KOL Engagement

HCP Relationship Management

Regulatory Knowledge

Autoimmune and Inflammatory Diseases

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free